Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 2015 Oct 13; 6(31):30487-99.

View in: PubMed

subject areas

ADP-ribosyl Cyclase 1
Antigens, CD34
Antineoplastic Agents
Apoptosis
bcl-X Protein
Biphenyl Compounds
Blast Crisis
Cell Proliferation
Enzyme Activation
Fusion Proteins, bcr-abl
Gene Expression Regulation, Leukemic
Humans
Imatinib Mesylate
Imidazoles
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Membrane Glycoproteins
Nitrophenols
Piperazines
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins c-mdm2
Pyrimidines
Sulfonamides
Tumor Cells, Cultured
Tumor Suppressor Protein p53

authors with profiles

MICHAEL ANDREEFF
HAGOP M KANTARJIAN
RICHARD E CHAMPLIN
MARINA KONOPLEVA
BING Z CARTER